Stay updated on OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The revision label on the page was updated from v3.5.4 to v3.5.5, indicating a routine backend/display update rather than a change to the study details.
    Difference
    0.0%
    Check dated 2026-06-05T12:33:40.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The study record now shows that results have been posted for OP-1250, replacing prior results-submission statuses, and includes detailed study design, eligibility criteria, cohorts, outcomes, and links to associated documents.
    Difference
    3%
    Check dated 2026-05-15T05:37:47.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The page footer now shows a newer ClinicalTrials.gov release revision identifier (“v3.5.3” instead of “v3.5.2”). This reflects a site/version update rather than a substantive change to the study details.
    Difference
    0.1%
    Check dated 2026-04-23T21:57:42.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    Footer revision label changed from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-16T18:34:44.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    Footer revision label updated from v3.4.3 to v3.5.0. No study details or user-facing content are affected.
    Difference
    0.1%
    Check dated 2026-03-18T20:48:40.000Z thumbnail image
  8. Check
    89 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T17:28:56.000Z thumbnail image

Stay in the know with updates to OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the OP-1250 Dose Escalation/Expansion in HR+, HER2- Breast Cancer Clinical Trial page.